Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Schizophrenia

  Free Subscription


Articles published in J Clin Psychopharmacol

Retrieve available abstracts of 105 articles:
HTML format



Single Articles


    March 2024
  1. KORKMAZ SA, Koca E, Yilmaz O, Ozbek T, et al
    Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
    J Clin Psychopharmacol. 2024 Mar 5. doi: 10.1097/JCP.0000000000001837.
    PubMed     Abstract available


  2. NAGANO M, Susuta Y, Masui H, Watanabe Y, et al
    Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    J Clin Psychopharmacol. 2024;44:107-116.
    PubMed     Abstract available


    February 2024
  3. MORI Y, Watanabe K, Suzuki Y, Ono H, et al
    Clozapine-Associated Myocarditis in a Patient With Schizophrenia Taking Lemborexant: A Case Report.
    J Clin Psychopharmacol. 2024 Feb 8. doi: 10.1097/JCP.0000000000001817.
    PubMed    


  4. DIMA A, Abdelsamie A, Clark-Castillo R, Webb-Wilson H, et al
    Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features.
    J Clin Psychopharmacol. 2024 Feb 5. doi: 10.1097/JCP.0000000000001819.
    PubMed    


    January 2024
  5. WATANABE M, Misawa F, Takeuchi H
    Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study.
    J Clin Psychopharmacol. 2024 Jan 26. doi: 10.1097/JCP.0000000000001804.
    PubMed     Abstract available


  6. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Reply to a Letter to the Editors From Dr de Souza and colleagues: "Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity".
    J Clin Psychopharmacol. 2024;44:76-78.
    PubMed    


  7. DE SOUZA JUNIOR SA, Cavalcante da Rocha ME, Marques Andrade AG, Fernandes de Moraes CL, et al
    Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity.
    J Clin Psychopharmacol. 2024;44:74-76.
    PubMed    


  8. MOHAMMAD-GHOLIZAD F, Karimzadeh I, Moghimi-Sarani E, Arshadi M, et al
    Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial
    J Clin Psychopharmacol. 2024;44:9-15.
    PubMed     Abstract available


  9. KARACAM DOGAN M, Yildiz FG, Temucin CM, Ertugrul A, et al
    Effects of Clozapine on Cortical Inhibition: A Transcranial Magnetic Stimulation Follow-up Study.
    J Clin Psychopharmacol. 2024;44:16-24.
    PubMed     Abstract available


    November 2023
  10. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Reply to Dr Yucel's Comments on the Article "Long-term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555-556.
    PubMed    


  11. YUCEL A
    Critical Feedback on Article by Lee and Colleagues: "Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555.
    PubMed    


  12. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis?: A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023;43:551-553.
    PubMed    


  13. MAGISTRI C, Mellini C
    Clozapine-Associated Agranulocytosis: A Systematic Review. Is It Really So Frighteningly Common?
    J Clin Psychopharmacol. 2023;43:527-533.
    PubMed     Abstract available


  14. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis: A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023;43:511-513.
    PubMed     Abstract available


    September 2023
  15. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis? A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023 Sep 29. doi: 10.1097/JCP.0000000000001766.
    PubMed    


  16. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis. A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023 Sep 7. doi: 10.1097/JCP.0000000000001758.
    PubMed     Abstract available


  17. TKACH N, Opler DJ
    A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023;43:481-482.
    PubMed    


  18. DE LIMA DN JR, Frota IJ, Macedo DS, Sanders LLO, et al
    Alpha Lipoic Acid for Schizophrenia: Future Investigations With Low Doses and Treatment-Resistant Patients-Reply to Letter by Kishi and Colleagues.
    J Clin Psychopharmacol. 2023;43:478-479.
    PubMed    


  19. KISHI T, Sakuma K, Miura G, Ito Y, et al
    Alpha Lipoic Acid for Schizophrenia: A Systematic Review and Meta-analysis.
    J Clin Psychopharmacol. 2023;43:477-478.
    PubMed    


  20. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023;43:472-474.
    PubMed    


  21. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023;43:468-469.
    PubMed    


    August 2023
  22. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023 Aug 8. doi: 10.1097/JCP.0000000000001737.
    PubMed    


  23. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023 Aug 8. doi: 10.1097/JCP.0000000000001746.
    PubMed    


  24. TKACH N, Opler DJ
    Letter to the Editors: A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023 Aug 7. doi: 10.1097/JCP.0000000000001743.
    PubMed    


    July 2023
  25. RODIN I, Evans A
    Case of Clozapine-Associated Negative Myoclonus.
    J Clin Psychopharmacol. 2023;43:386-387.
    PubMed    


    May 2023
  26. ONITSUKA T, Okada T, Hasegawa N, Tsuboi T, et al
    Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
    J Clin Psychopharmacol. 2023 May 23. doi: 10.1097/JCP.0000000000001704.
    PubMed     Abstract available



  27. Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses: Erratum.
    J Clin Psychopharmacol. 2023;43:304.
    PubMed    


  28. STREIFF RA
    Institutional Neglect of Anosognosia Is a Critical Barrier in the Treatment of Psychosis Related Disorders.
    J Clin Psychopharmacol. 2023;43:200-203.
    PubMed    


    April 2023
  29. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).
    J Clin Psychopharmacol. 2023 Apr 22. doi: 10.1097/JCP.0000000000001679.
    PubMed     Abstract available


  30. MALHAM KM, Miller BJ
    Long-Acting Injectable Antipsychotics and Infections in Schizophrenia.
    J Clin Psychopharmacol. 2023 Apr 18. doi: 10.1097/JCP.0000000000001694.
    PubMed     Abstract available


    March 2023
  31. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2023 Mar 29. doi: 10.1097/JCP.0000000000001671.
    PubMed     Abstract available


  32. MALALI METIN H, Aksu T, Akyildiz UO, Sevincok L, et al
    Cerebellar Cognitive Affective Syndrome and Delusional Disorder Associated With Long-Term Phenytoin Use: A Case Report.
    J Clin Psychopharmacol. 2023;43:184-186.
    PubMed    


    February 2023
  33. OLIVOLA M, Arienti V, Bassetti N, Giovanna G, et al
    Lurasidone Augmentation of Clozapine in Refractory Schizophrenia: A Case Series.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001662.
    PubMed     Abstract available


  34. BOGERS JPAM, Schulte PFJ, Broekman TG, de Haan L, et al
    Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001657.
    PubMed     Abstract available


  35. LAGREULA J, Ferraiolo M, De Timary P, Delatte B, et al
    Impact of a Caffeine Restriction Policy on Inpatients With Schizophrenia: A Pre-Post Comparison Using Electronic Health Records.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001670.
    PubMed     Abstract available


  36. ARMSTRONG AG, Preskorn SH
    Thoughts on the Value of Case Series in the Literature: An Example Using the Article on Lurasidone Augmentation of Clozapine in Refractory Schizophrenia.
    J Clin Psychopharmacol. 2023 Feb 24. doi: 10.1097/JCP.0000000000001676.
    PubMed    


  37. TIRUPATI S
    Ultra-Treatment-Resistant Schizophrenia and Clozapine Augmentation.
    J Clin Psychopharmacol. 2023 Feb 1. doi: 10.1097/JCP.0000000000001652.
    PubMed    


    January 2023
  38. SHUKLA A, Nandan NK, Singh LK
    Acute Psychosis After Immunization With Whole-Virion Inactivated COVID-19 Vaccine; A Case Report From Central India.
    J Clin Psychopharmacol. 2023;43:66-67.
    PubMed    


  39. DE LIMA DN JR, Costa Filho CWL, Frota IJ, de Oliveira ALB, et al
    alpha-Lipoic Acid as Adjunctive Treatment for Schizophrenia: A Randomized Double-Blind Study.
    J Clin Psychopharmacol. 2023;43:39-45.
    PubMed     Abstract available


  40. CUOMO A, Aguglia E, Biagini S, Carano A, et al
    Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia.
    J Clin Psychopharmacol. 2023;43:35-38.
    PubMed     Abstract available


    November 2022
  41. KIM K, Kim YS, Joo EJ, Kim EJ, et al
    Clozapine Blood Concentration Predicts Corrected QT-Interval Prolongation in Patients With Psychoses.
    J Clin Psychopharmacol. 2022;42:536-543.
    PubMed     Abstract available


  42. CONTRUCCI RR, Heikens M, Beex-Oosterhuis MM
    Case Report: Blepharospasms After the Use of Long-Acting Paliperidone Injections.
    J Clin Psychopharmacol. 2022;42:608-609.
    PubMed    


    October 2022
  43. DING J, Zhang Y, Zhang Y, Yang L, et al
    Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
    J Clin Psychopharmacol. 2022 Oct 25. pii: 00004714-990000000-00067.
    PubMed     Abstract available


  44. JU V, Walkerly A, VandenBerg A, Shobassy A, et al
    New Onset of Seizures and Psychosis in a Patient Who Is Coprescribed Atomoxetine and Bupropion: A Case Report.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00056.
    PubMed    


  45. OKADA T, Hori H, Hasegawa N, Murata A, et al
    Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00057.
    PubMed    


  46. DARWISH M, Bugarski-Kirola D, Passarell J, Owen J, et al
    Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study.
    J Clin Psychopharmacol. 2022 Oct 3. pii: 00004714-990000000-00053.
    PubMed     Abstract available


    September 2022
  47. TEODORO T, Nogueira V, Aldeias J, Teles Martins M, et al
    Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00049.
    PubMed    


  48. HORIKOSHI S, Miura I, Mui A, Hikichi T, et al
    Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia: Retrospective, A 4-Year Mirror-Image Study.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00048.
    PubMed     Abstract available


  49. KANE JM
    A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
    J Clin Psychopharmacol. 2022;42.
    PubMed     Abstract available


  50. SATODIYA RM, Brown VR, Njuguna SW, Bied AM, et al
    A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight.
    J Clin Psychopharmacol. 2022;42:495-499.
    PubMed     Abstract available


    August 2022
  51. ZHAND N, Labelle A, Ghanem D, Gujral P, et al
    Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.
    J Clin Psychopharmacol. 2022 Aug 17. pii: 00004714-990000000-00044.
    PubMed     Abstract available


    July 2022
  52. TIEN Y, Huang SC
    Aripiprazole-Associated Acute Dystonia During Dose Reduction in Patient With Schizophrenia and Dementia: A Case Report.
    J Clin Psychopharmacol. 2022 Jul 2. pii: 00004714-990000000-00031.
    PubMed    


  53. GROVER S, Naskar C, Chakrabarti S
    Factors Associated With Poor Response to Clozapine in Schizophrenia: A Study From Northern India.
    J Clin Psychopharmacol. 2022;42:345-349.
    PubMed     Abstract available


  54. GONZALEZ-RODRIGUEZ A, Monreal JA
    Time for Rational Pharmacotherapy in Delusional Disorder: New Targets for Old Clinical Observations.
    J Clin Psychopharmacol. 2022;42:413-414.
    PubMed    


  55. BECHARD L, Morasse-Begis M, Corbeil O, Hakim JR, et al
    Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series.
    J Clin Psychopharmacol. 2022;42:391-395.
    PubMed     Abstract available


    June 2022
  56. KOGURE M, Kanahara N, Kimura M, Hanaoka S, et al
    Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
    J Clin Psychopharmacol. 2022 Jun 17. pii: 00004714-990000000-00026.
    PubMed     Abstract available


  57. CHIU CC, Lin C, Chen WY, Chen CR, et al
    Therapeutic Drug Monitoring of Paliperidone in Patients With Schizophrenia in Taiwan.
    J Clin Psychopharmacol. 2022 Jun 14. pii: 00004714-990000000-00023.
    PubMed     Abstract available


  58. WANG D, Wei N, Hu F, Li J, et al
    Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.
    J Clin Psychopharmacol. 2022 Jun 10. pii: 00004714-990000000-00019.
    PubMed     Abstract available


    May 2022
  59. GALLAGHER KE, Funaro MC, Woods SW
    Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
    J Clin Psychopharmacol. 2022;42:308-314.
    PubMed     Abstract available


    March 2022
  60. YEE CS, Bahji A, Lolich M, Vazquez GH, et al
    Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.
    J Clin Psychopharmacol. 2022;42:198-208.
    PubMed     Abstract available


  61. FRANKENBURG FR, Malvesti S
    Paliperidone and Edema.
    J Clin Psychopharmacol. 2022;42:225-226.
    PubMed    


    February 2022
  62. TAKAKI M, Yada Y, Sakamoto S, Fujiwara M, et al
    A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine.
    J Clin Psychopharmacol. 2022 Feb 10. pii: 00004714-900000000-98207.
    PubMed    


    January 2022
  63. WANG XY, Chan HY, Lin CH
    Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia: A 17-Year Retrospective Cohort Study.
    J Clin Psychopharmacol. 2022 Jan 6. pii: 00004714-900000000-98219.
    PubMed     Abstract available


  64. CINTRON PASTRANA MA, Quintana Aviles E
    Treatment of Refractory Schizophrenia With Clozapine in a Patient With Wolff-Parkinson-White Syndrome.
    J Clin Psychopharmacol. 2022;42:95-96.
    PubMed    


  65. HE L, Yu Y, Zhang L, He S, et al
    A Real-World Study of Risk Factors for QTc Prolongation in Schizophrenia Patients Receiving Atypical Antipsychotics.
    J Clin Psychopharmacol. 2022;42:71-74.
    PubMed     Abstract available


  66. SMITH RL, Wollmann BM, Kylleso L, Tran TTA, et al
    Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022;42:43-50.
    PubMed     Abstract available


  67. STROMME MF, Mellesdal LS, Bartz-Johannesen CA, Kroken RA, et al
    Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.
    J Clin Psychopharmacol. 2022;42:37-42.
    PubMed     Abstract available


  68. GARRIGA M, Mallorqui A, Bernad S, Ruiz-Cortes V, et al
    Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.
    J Clin Psychopharmacol. 2022;42:75-80.
    PubMed     Abstract available


  69. BONNET U, Knierim U, Ronge R, Jahn J, et al
    Late-Onset Polyserositis Emerging During Long-Term Clozapine Treatment and Persisting After Clozapine Discontinuation: Is Clozapine Really Innocent?
    J Clin Psychopharmacol. 2022;42:106-107.
    PubMed    


  70. ERDOGAN A, Ilhan F
    Risperidone-Associated Acute Laryngeal Dystonia: A Case Report.
    J Clin Psychopharmacol. 2022;42:98-99.
    PubMed    


    November 2021
  71. MAURI MC, Franco G, Minutillo A, Paletta S, et al
    The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data).
    J Clin Psychopharmacol. 2021 Nov 24. pii: 00004714-900000000-98229.
    PubMed     Abstract available


  72. RUDA D, Jensen KG, Decara MS, Klauber DG, et al
    CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
    J Clin Psychopharmacol. 2021;41:667-672.
    PubMed     Abstract available


  73. WEIZMAN S, Shelef A, Bloemhof Bris E, Stryjer R, et al
    A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.
    J Clin Psychopharmacol. 2021;41:629-631.
    PubMed     Abstract available


  74. COMAI S, Fuamba Y, Rivolta MC, Gobbi G, et al
    Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital.
    J Clin Psychopharmacol. 2021;41:623-628.
    PubMed     Abstract available


  75. MAKHLOUF AT, Van Alphen MU, Manzano GS, Freudenreich O, et al
    A Seizure After COVID-19 Vaccination in a Patient on Clozapine.
    J Clin Psychopharmacol. 2021;41:689-690.
    PubMed    


  76. CELLINI L, De Donatis D, Mercolini L, Panariello F, et al
    Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels: A Case Series.
    J Clin Psychopharmacol. 2021;41:694-696.
    PubMed    


  77. OKEYA K, Misawa F, Fujii Y, Takeuchi H, et al
    Olanzapine Reduction From High Dose to Standard Dose: A Retrospective Chart Review.
    J Clin Psychopharmacol. 2021;41:676-680.
    PubMed     Abstract available


  78. SELCUK M
    Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg Syndrome: A Case Report.
    J Clin Psychopharmacol. 2021;41:692-694.
    PubMed    


    September 2021
  79. SRIFUENGFUNG M, Sukakul T, Pummangura C, Srifuengfung S, et al
    Oral Ulcers as an Unpredictable Adverse Reaction to Quetiapine Use in a Patient With Schizophrenia.
    J Clin Psychopharmacol. 2021 Sep 9. pii: 00004714-900000000-98247.
    PubMed    


  80. MASHIMA Y, Uchida H, Kinoshita S, Arita Y, et al
    Camptocormia Secondary to Antipsychotic-Associated Dystonia of the Rectus Abdominis Muscles Detected by Abdominal Computed Tomography: A Case Report.
    J Clin Psychopharmacol. 2021;41:608-610.
    PubMed    


  81. CUOMO A, Chioccioli M, Cattaneo CI, Magnani PA, et al
    Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation: A Naturalistic, Retrospective, and Observational Study.
    J Clin Psychopharmacol. 2021;41:613-614.
    PubMed    


    August 2021
  82. PEITL V, Badzim VA, Sisko Markos I, Rendulic A, et al
    Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole.
    J Clin Psychopharmacol. 2021 Aug 26. pii: 00004714-900000000-98248.
    PubMed     Abstract available


  83. OGAWA T, Tachikawa H, Shiratori Y, Sodeyama N, et al
    Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study.
    J Clin Psychopharmacol. 2021 Aug 23. pii: 00004714-900000000-98251.
    PubMed    


  84. LIM M, Li Z, Xie H, Tan BL, et al
    The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia.
    J Clin Psychopharmacol. 2021 Aug 13. pii: 00004714-900000000-98260.
    PubMed     Abstract available


    July 2021

  85. Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2021;41:507.
    PubMed    


  86. AFTAB R, Pereira M, Hewitt J, Whale R, et al
    Effectiveness and Predictors of Discontinuation of Aripiprazole Long-acting Injection: A 12-Month Naturalistic Cohort Study.
    J Clin Psychopharmacol. 2021;41:478-483.
    PubMed     Abstract available


  87. GLICK ID, Cerfolio NE, Kamis D, Laurence M, et al
    Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness.
    J Clin Psychopharmacol. 2021;41:366-369.
    PubMed     Abstract available


  88. SINKEVICIUTE I, Hugdahl K, Bartz-Johannessen C, Kroken RA, et al
    Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
    J Clin Psychopharmacol. 2021;41:389-396.
    PubMed     Abstract available


  89. SUHAS S, Manchegowda S, Venkatasubramanian G, Kumar V, et al
    Clozapine and Oral Contraceptives-Implications Beyond Pharmacokinetics: A Case Report.
    J Clin Psychopharmacol. 2021;41:487-490.
    PubMed    


    June 2021
  90. KOREKI A, Mori H, Nozaki S, Koizumi T, et al
    Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs: A Cross-sectional Study.
    J Clin Psychopharmacol. 2021 Jun 4. pii: 00004714-900000000-98299.
    PubMed     Abstract available


    May 2021
  91. SUHAS S, Shivani S, Singh GK, Venkatasubramanian G, et al
    Festina Lente: Betahistine for Clozapine-Associated Weight Gain: A Case Report.
    J Clin Psychopharmacol. 2021;41:332-333.
    PubMed    


  92. SUZUKI K, Castelli M, Komaroff M, Starling B, et al
    Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
    J Clin Psychopharmacol. 2021;41:286-294.
    PubMed     Abstract available


  93. MATHUR R, Singh J, Sood M
    A Case Report of Clozapine-Associated Stuttering and Amisulpride-Associated Stuttering and Seizure in an Adult on Concurrent Fluoxetine Therapy.
    J Clin Psychopharmacol. 2021;41:330-332.
    PubMed    


  94. TIRUPATI S, Gordon T
    Continuation of Treatment With Clozapine After an Episode of Neutropenia.
    J Clin Psychopharmacol. 2021;41:320-322.
    PubMed     Abstract available


    April 2021
  95. GUIMARAES TM, Guimaraes MRC, Oliveira IAF, Leoni RF, et al
    Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia: A Randomized Controlled Crossover Trial.
    J Clin Psychopharmacol. 2021 Apr 14. pii: 00004714-900000000-98311.
    PubMed     Abstract available


  96. LINDENMAYER JP, Rizvi S
    Augmentation With Pimavanserin in Treatment Refractory Schizophrenia: Case Report.
    J Clin Psychopharmacol. 2021 Apr 13. pii: 00004714-900000000-98312.
    PubMed    


    March 2021
  97. AN H, Fan H, Chen S, Qi S, et al
    Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98320.
    PubMed     Abstract available


  98. WANG J, Hart KL, Qi W, Ardekani BA, et al
    Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia.
    J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98319.
    PubMed     Abstract available


  99. REHIMINI S, Goddard KG, Margolese HC
    Exceptionally High Clozapine-Associated Eosinophilia.
    J Clin Psychopharmacol. 2021;41:216-218.
    PubMed    


  100. GROVER S, Naskar C, Chakrabarti S
    Does the Starting of Clozapine Influence Coprescription of Other Medications?: A Study From India.
    J Clin Psychopharmacol. 2021;41:148-154.
    PubMed     Abstract available


  101. GRIFFIN JM, Woznica E, Gilotra NA, Nucifora FC Jr, et al
    Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge.
    J Clin Psychopharmacol. 2021;41:180-185.
    PubMed     Abstract available


  102. YILDIZ MI, Karacam Dogan M, Mutlu E, Abdullayeva L, et al
    All in One: Clozapine-Associated Acute Pancreatitis With Multiple Organ Involvement.
    J Clin Psychopharmacol. 2021;41:214-216.
    PubMed    


  103. KHURRAM SK, Ames M, Muniz J
    Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    J Clin Psychopharmacol. 2021;41:220-221.
    PubMed    


  104. MISAWA F, Fujii Y, Takeuchi H
    Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in Japan.
    J Clin Psychopharmacol. 2021;41:206-207.
    PubMed    


  105. DANILEWITZ M, Rafizadeh R, Bousman CA
    Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis: A Case Report.
    J Clin Psychopharmacol. 2021;41:218-220.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.